STAT3 and head and neck squamous cell carcinoma: Authors observed that, during dasatinib treatment, tumor progression was associated with a hyper-activation of STAT3, an event that could be considered as a de novo acquired mechanism of resistance to dasatinib in HNSCC patients [103].